XML 78 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]    
Primary sources of revenue, description We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).  
Revenue recognized   $ 3,000,000.0
Deferred revenue $ 1,850,000 $ 3,532,000
Revenue | Minimum | Customer Concentration Risk | Medicare    
Disaggregation Of Revenue [Line Items]    
Concentration risk, percentage 18.00% 17.00%
Other Long-term Liabilities    
Disaggregation Of Revenue [Line Items]    
Non-current deferred revenue $ 800 $ 1,400,000
Up Front Cash Payments    
Disaggregation Of Revenue [Line Items]    
Deferred revenue $ 1,400,000